Literature DB >> 11500507

MD-2 binds to bacterial lipopolysaccharide.

S Viriyakosol1, P S Tobias, R L Kitchens, T N Kirkland.   

Abstract

The exact roles and abilities of the individual components of the lipopolysaccharide (LPS) receptor complex of proteins remain unclear. MD-2 is a molecule found in association with toll-like receptor 4. We produced recombinant human MD-2 to explore its LPS binding ability and role in the LPS receptor complex. MD-2 binds to highly purified rough LPS derived from Salmonella minnesota and Escherichia coli in five different assays; one assay yielded an apparent KD of 65 nm. MD-2 binding to LPS did not require LPS-binding proteins LBP and CD14; in fact LBP competed with MD-2 for LPS. MD-2 enhanced the biological activity of LPS in toll-like receptor 4-transfected Chinese hamster ovary cells but inhibited LPS activation of U373 astrocytoma cells and of monocytes in human whole blood. These data indicate that MD-2 is a genuine LPS-binding protein and strongly suggest that MD-2 could play a role in regulation of cellular activation by LPS depending on its local availability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500507     DOI: 10.1074/jbc.M105228200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

Review 1.  The potential for Toll-like receptors to collaborate with other innate immune receptors.

Authors:  Subhankar Mukhopadhyay; Jurgen Herre; Gordon D Brown; Siamon Gordon
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

2.  Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling.

Authors:  Pearl Gray; Kathrin S Michelsen; Cherilyn M Sirois; Emily Lowe; Kenichi Shimada; Timothy R Crother; Shuang Chen; Constantinos Brikos; Yonca Bulut; Eicke Latz; David Underhill; Moshe Arditi
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

Review 3.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

4.  Comparison of lipopolysaccharide-binding functions of CD14 and MD-2.

Authors:  Jun Koraha; Naoko Tsuneyoshi; Masao Kimoto; Jean-Francois Gauchat; Hiroshi Nakatake; Kenji Fukudome
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 5.  Role of Toll-like receptors in infection and immunity: clinical implications.

Authors:  Patricia Cristofaro; Steven M Opal
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2.

Authors:  Umeharu Ohto; Koichi Fukase; Kensuke Miyake; Toshiyuki Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-24       Impact factor: 11.205

7.  The role of disulfide bonds in the assembly and function of MD-2.

Authors:  Gregory E D Mullen; Margaret N Kennedy; Alberto Visintin; Alessandra Mazzoni; Cynthia A Leifer; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 8.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

9.  MD-2 is necessary for the toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface.

Authors:  Takahiro Ohnishi; Masashi Muroi; Ken-Ichi Tanamoto
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

10.  Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling.

Authors:  Vishal Jain; Annett Halle; Kristen A Halmen; Egil Lien; Marie Charrel-Dennis; Sanjay Ram; Douglas T Golenbock; Alberto Visintin
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.